(Q37867102)

24 August 2017

1 reference

title

Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems (English)

1 reference

24 August 2017

1 reference

Nathalie Garçon

1

1 reference

PubMed ID

21506645

24 August 2017

Marcelle Van Mechelen

series ordinal

2

1 reference

24 August 2017

1 April 2011

1 reference

Expert Review of Vaccines

24 August 2017

1 reference

24 August 2017

10

1 reference

24 August 2017

4

1 reference

24 August 2017

471-486

1 reference

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

24 August 2017

1 reference

Immunological foundations to the quest for new vaccine adjuvants

21 January 2018

1 reference

The perfect mix: recent progress in adjuvant research

21 January 2018

1 reference

Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists

21 January 2018

1 reference

Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine.

21 January 2018

1 reference

Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma

21 January 2018

1 reference

Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalane in malaria circumsporozoite protein vaccine

21 January 2018

1 reference

Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers

21 January 2018

1 reference

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

21 January 2018

1 reference

Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant

21 January 2018

1 reference

Vaccine adjuvants: putting innate immunity to work

21 January 2018

1 reference

The ABC of clinical and experimental adjuvants--a brief overview

21 January 2018

1 reference

The instructive role of innate immunity in the acquired immune response

21 January 2018

1 reference

Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene

21 January 2018

1 reference

Innate immune sensing and its roots: the story of endotoxin

21 January 2018

1 reference

RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides

21 January 2018

1 reference

Molecular identification of a danger signal that alerts the immune system to dying cells

21 January 2018

1 reference

Innate immunity: the virtues of a nonclonal system of recognition

21 January 2018

1 reference

A human homologue of the Drosophila Toll protein signals activation of adaptive immunity

21 January 2018

1 reference

Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant

21 January 2018

1 reference

AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity

21 January 2018

1 reference

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

21 January 2018

1 reference

Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice

21 January 2018

1 reference

Monocyte-mediated defense against microbial pathogens.

21 January 2018

1 reference

(How) do aluminium adjuvants work?

21 January 2018

1 reference

Interleukin-6/STAT3 signaling regulates the ability of naive T cells to acquire B-cell help capacities

21 January 2018

1 reference

Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity

21 January 2018

1 reference

Altered immunomodulating and toxicological properties of degraded Quillaja saponaria Molina saponins.

21 January 2018

1 reference

QS-21 structure/function studies: effect of acylation on adjuvant activity

21 January 2018

1 reference

Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen

21 January 2018

1 reference

Preclinical evaluation of the safety and immunogenicity of a vaccine consisting of Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS,S/AS01B vaccine in rhesus primates

21 January 2018

1 reference

Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma.

21 January 2018

1 reference

Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys.

21 January 2018

1 reference

From vaccines to memory and back

21 January 2018

1 reference

Vaccines: correlates of vaccine-induced immunity

21 January 2018

1 reference

Rapid cloning of high-affinity human monoclonal antibodies against influenza virus

21 January 2018

1 reference

21 January 2018

1 reference

Adaptation of humoral memory

21 January 2018

1 reference

Organization of immunological memory by bone marrow stroma

21 January 2018

1 reference

Competence and competition: the challenge of becoming a long-lived plasma cell

21 January 2018

1 reference

Differentiation of memory B and T cells

21 January 2018

1 reference

Central memory and effector memory T cell subsets: function, generation, and maintenance

21 January 2018

1 reference

Preferential localization of effector memory cells in nonlymphoid tissue

21 January 2018

1 reference

A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells

21 January 2018

1 reference

The causal relation between human papillomavirus and cervical cancer

21 January 2018

1 reference

Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis

21 January 2018

1 reference

Papillomaviruses in the causation of human cancers - a brief historical account

21 January 2018

1 reference

Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis

21 January 2018

1 reference

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

21 January 2018

1 reference

Epidemiologic classification of human papillomavirus types associated with cervical cancer

21 January 2018

1 reference

A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women

21 January 2018

1 reference

Epidemiology of Genital Human Papillomavirus Infection

21 January 2018

1 reference

The epidemiology of human papillomavirus infections

21 January 2018

1 reference

Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature

21 January 2018

1 reference

Human papillomavirus and cervical cancer

21 January 2018

1 reference

Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix™, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine

21 January 2018

1 reference

Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women

21 January 2018

1 reference

Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years

21 January 2018

1 reference

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

21 January 2018

1 reference

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

21 January 2018

1 reference

AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention

21 January 2018

1 reference

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years

21 January 2018

1 reference

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

21 January 2018

1 reference

Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women

21 January 2018

1 reference

Immunogenicity, reactogenicity, and safety of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women: interim analysis of a phase II, double-blind, randomized controlled trial at month 7.

21 January 2018

1 reference

Vaccination with a human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine in Korean girls aged 10-14 years

21 January 2018

1 reference

Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses

21 January 2018

1 reference

Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years

21 January 2018

1 reference

Safety and Immunogenicity of the HPV-16/18 AS04-Adjuvanted Vaccine: A Randomized, Controlled Trial in Adolescent Girls

21 January 2018

1 reference

Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix

21 January 2018

1 reference

Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women.

21 January 2018

1 reference

Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients

21 January 2018

1 reference

New concepts in herpes simplex virus vaccine development: notes from the battlefield

21 January 2018

1 reference

Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review

21 January 2018

1 reference

The cycle of human herpes simplex virus infection: virus transport and immune control

21 January 2018

1 reference

Maternal and neonatal herpes simplex virus infections

21 January 2018

1 reference

An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection

21 January 2018

1 reference

Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs

21 January 2018

1 reference

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

21 January 2018

1 reference

Malaria: progress, perils, and prospects for eradication

21 January 2018

1 reference

From the circumsporozoite protein to the RTS, S/AS candidate vaccine

21 January 2018

1 reference

Plasmodium circumsporozoite protein promotes the development of the liver stages of the parasite

21 January 2018

1 reference

Developmental biology of sporozoite-host interactions in Plasmodium falciparum malaria: implications for vaccine design

21 January 2018

1 reference

Efficacy of murine malaria sporozoite vaccines: implications for human vaccine development.

21 January 2018

1 reference

Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection

21 January 2018

1 reference

Cellular effector mechanisms against Plasmodium liver stages

21 January 2018

1 reference

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial

21 January 2018

1 reference

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

21 January 2018

1 reference

Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial

21 January 2018

1 reference

Plasmodium falciparum malaria vaccines in development

21 January 2018

1 reference

Development of the RTS,S/AS malaria candidate vaccine

21 January 2018

1 reference

Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children

21 January 2018

1 reference

Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial

21 January 2018

1 reference

Plasmodium falciparum-specific cellular immune responses after immunization with the RTS,S/AS02D candidate malaria vaccine in infants living in an area of high endemicity in Mozambique

21 January 2018

1 reference

Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants

21 January 2018

1 reference

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age

21 January 2018

1 reference

Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection

21 January 2018

1 reference

Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area.

21 January 2018

1 reference

Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial

21 January 2018

1 reference

Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A.

21 January 2018

1 reference

Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone

21 January 2018

1 reference

Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children

21 January 2018

1 reference

A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon

21 January 2018

1 reference

Insights into long-lasting protection induced by RTS,S/AS02A malaria vaccine: further results from a phase IIb trial in Mozambican children

21 January 2018

1 reference

The synthetic Plasmodium falciparum circumsporozoite peptide PfCS102 as a malaria vaccine candidate: a randomized controlled phase I trial

21 January 2018

1 reference

Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.

21 January 2018

1 reference

Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.

21 January 2018

1 reference

Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial

21 January 2018

1 reference

Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial

21 January 2018

1 reference

Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02.

21 January 2018

1 reference

Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya

21 January 2018

1 reference

Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection

21 January 2018

1 reference

Differential localization of full-length and processed forms of PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum merozoites.

21 January 2018

1 reference

The major merozoite surface protein as a malaria vaccine target

21 January 2018

1 reference

Pre-erythrocytic immunity to Plasmodium falciparum: the case for an LSA-1 vaccine

21 January 2018

1 reference

A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites

21 January 2018

1 reference

Induction of immunity to human immunodeficiency virus type-1 by vaccination

21 January 2018

1 reference

Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need?

21 January 2018

1 reference

Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.

21 January 2018

1 reference

Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems.

21 January 2018

1 reference

An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers

21 January 2018

1 reference

Cross-reactivity of anti-HIV-1 T cell immune responses among the major HIV-1 clades in HIV-1-positive individuals from 4 continents

21 January 2018

1 reference

Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study

21 January 2018

1 reference

Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three cytokines

21 January 2018

1 reference

Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells

21 January 2018

1 reference

CD8+ cytotoxic T lymphocyte responses to lentiviruses and herpesviruses

21 January 2018

1 reference

HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells

21 January 2018

1 reference

Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques.

21 January 2018

1 reference

Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers

21 January 2018

1 reference

Fc receptor but not complement binding is important in antibody protection against HIV.

21 January 2018

1 reference

Tuberculosis vaccines - an update.

21 January 2018

1 reference

The population dynamics and control of tuberculosis

21 January 2018

1 reference

Tuberculosis: what we don't know can, and does, hurt us.

21 January 2018

1 reference

New vaccines for tuberculosis

21 January 2018

1 reference

Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys

21 January 2018

1 reference

Recent findings in immunology give tuberculosis vaccines a new boost

21 January 2018

1 reference

Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine

21 January 2018

1 reference

Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.

21 January 2018

1 reference

Safety and immunogenicity of an investigational adjuvanted hepatitis B vaccine (HB-AS02V) in healthy adults

21 January 2018

1 reference

Immunotherapy in the landscape of new targeted treatments for non-small cell lung cancer

21 January 2018

1 reference

Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors.

21 January 2018

1 reference

Tumor antigens recognized by T lymphocytes

21 January 2018

1 reference

Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients.

21 January 2018

1 reference

Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming

21 January 2018

1 reference

T cells and viral persistence: lessons from diverse infections

21 January 2018

1 reference

Immune-response profiles induced by human immunodeficiency virus type 1 vaccine DNA, protein or mixed-modality immunization: increased protection from pathogenic simian-human immunodeficiency virus viraemia with protein/DNA combination

21 January 2018

1 reference

Safety of the RTS,S/AS02A malaria vaccine in Mozambican children during a Phase IIb trial.

21 January 2018

1 reference

Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research

21 January 2018

1 reference

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

21 January 2018

1 reference

A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients

21 January 2018

1 reference

Therapeutic potentiation of the immune system by costimulatory Schiff-base-forming drugs

21 January 2018

1 reference

Non-CS pre-erythrocytic protective antigens

21 January 2018

1 reference

Immunology and the elusive AIDS vaccine

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERV.11.29

1 reference

24 August 2017

1 reference

PubMed ID

21506645